Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Cogent Biosciences(US:COGT) Globenewswireยท2025-08-05 12:00Anticipated Upcoming Milestones Announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients. The SUMMIT trial, which was designed to assess the clinical benefit of bezuclastinib versus placebo, achieved its primary endpoint with a highly statistically significant difference in the mean change in Total Symptom Score (TSS) at 24 weeks (p=0.0002). TSS was assessed by the Mastocytosis Symptom Severity Daily Diary ...